Cover Image
市場調查報告書

腦損傷:開發平台分析

Brain Injury - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 246010
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
腦損傷:開發平台分析 Brain Injury - Pipeline Review, H2 2015
出版日期: 2015年07月22日 內容資訊: 英文 47 Pages
簡介

所謂腦損傷是指來自外部機械力造成腦功能無法運作的狀態。通常主要的原因是對頭部·人體的激烈衝擊·休克。主要症狀有頭痛和噁心·嘔吐,倦怠感·睡意,暈眩·喪失平衡感,失去意識,記憶力衰退,集中力降低等。易罹病素質有高齡化等。

本報告提供全球各國治療腦損傷所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

腦損傷概要

治療藥的開發

  • 腦損傷開發中產品:概要
  • 腦損傷開發中產品:比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Acorda Therapeutics, Inc.
  • Biogen, Inc.
  • Chiesi Farmaceutici SpA
  • Faron Pharmaceuticals Oy
  • FibroGen, Inc.
  • Virogenomics, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury
  • FG-4497
  • interferon beta-1a
  • Peptide to Inhibit Pannexin-1 for Brain Injury
  • PRE-084
  • Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
  • Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury
  • RTL-551
  • Small Molecules to Block TRPC3 for Acute Brain Injury
  • Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury
  • Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury

最新開發平台趨勢

暫停中的計劃

開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC6894IDB

Summary

Global Markets Direct's, 'Brain Injury - Pipeline Review, H2 2015', provides an overview of the Brain Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Brain Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Brain Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Brain Injury Overview
  • Therapeutics Development
    • Pipeline Products for Brain Injury - Overview
    • Pipeline Products for Brain Injury - Comparative Analysis
  • Brain Injury - Therapeutics under Development by Companies
  • Brain Injury - Therapeutics under Investigation by Universities/Institutes
  • Brain Injury - Pipeline Products Glance
    • Early Stage Products
  • Brain Injury - Products under Development by Companies
  • Brain Injury - Products under Investigation by Universities/Institutes
  • Brain Injury - Companies Involved in Therapeutics Development
    • Acorda Therapeutics, Inc.
    • Biogen, Inc.
    • Chiesi Farmaceutici SpA
    • Faron Pharmaceuticals Oy
    • FibroGen, Inc.
    • Virogenomics, Inc.
  • Brain Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FG-4497 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Inhibit Pannexin-1 for Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRE-084 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTL-551 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block TRPC3 for Acute Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Brain Injury - Recent Pipeline Updates
  • Brain Injury - Dormant Projects
  • Brain Injury - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Brain Injury, H2 2015
  • Number of Products under Development for Brain Injury - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Brain Injury - Pipeline by Acorda Therapeutics, Inc., H2 2015
  • Brain Injury - Pipeline by Biogen, Inc., H2 2015
  • Brain Injury - Pipeline by Chiesi Farmaceutici SpA, H2 2015
  • Brain Injury - Pipeline by Faron Pharmaceuticals Oy, H2 2015
  • Brain Injury - Pipeline by FibroGen, Inc., H2 2015
  • Brain Injury - Pipeline by Virogenomics, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Brain Injury Therapeutics - Recent Pipeline Updates, H2 2015
  • Brain Injury - Dormant Projects, H2 2015
  • Brain Injury - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Brain Injury, H2 2015
  • Number of Products under Development for Brain Injury - Comparative Analysis, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
Back to Top